Home » Healthcare » United States Human Insulin Market

United States Human Insulin Market

United States Human Insulin Market By Device (Pens, Syringes, Others); By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes); By Insulin (Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, Others); By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
United States Human Insulin Market Size 2023	USD 6,123.09 million
United States Human Insulin Market, CAGR	4.60%
United States Human Insulin Market Size 2032	USD 9,178.30 million

Market Overview

United States Human Insulin market size was valued at USD 6,123.09 million in 2023 and is anticipated to reach USD 9,178.30 million by 2032, at a CAGR of 4.60% during the forecast period (2023-2032).

The United States Human Insulin market is driven by the rising prevalence of diabetes, particularly type 1 and type 2, which increases the demand for insulin therapies. Technological advancements in insulin delivery systems, such as insulin pens, pumps, and continuous glucose monitoring, are also contributing to market growth by enhancing convenience and improving patient outcomes. The aging population further amplifies demand as older adults are more susceptible to developing diabetes. Additionally, increasing healthcare awareness and the growing focus on early diabetes diagnosis and management are key factors fostering market expansion. Trends such as biosimilar insulin products, which offer more affordable alternatives to branded insulins, and the shift towards personalized treatment plans are shaping the market. The ongoing evolution of insulin formulations, including rapid-acting and long-acting varieties, ensures that patients have access to more tailored and efficient treatment options, further supporting market growth.

The United States human insulin market is geographically diverse, with significant demand across various regions, driven by the increasing prevalence of diabetes and the need for affordable treatment options. Major players in the market, such as Novo Nordisk, Eli Lilly, and Sanofi, dominate the landscape with their established insulin products and innovative therapies. These companies are actively involved in expanding their presence through the introduction of biosimilars, advanced insulin delivery systems, and partnerships with healthcare providers. Additionally, emerging players like MannKind Corporation and Biocon are gaining traction with their unique insulin formulations and devices. Geographically, regions like the Southern and Midwestern U.S. experience a higher concentration of diabetes cases, fueling demand for insulin. Meanwhile, the Western and Northeastern regions are focused on advancing diabetes care through the adoption of newer technologies, such as insulin pumps and continuous glucose monitoring, creating a dynamic and competitive environment for insulin manufacturers.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The United States human insulin market was valued at USD 6,123.09 million in 2023 and is expected to reach USD 9,178.30 million by 2032, growing at a CAGR of 4.60% from 2023 to 2032.

The global human insulin market was valued at USD 21,000 million in 2023 and is projected to reach USD 31,208 million by 2032, growing at a CAGR of 4.50% from 2023 to 2032.
Rising prevalence of diabetes, especially type 2 diabetes, is driving the demand for insulin therapies.

Increasing adoption of biosimilar insulins offers more affordable alternatives, stimulating market growth.
Advancements in insulin delivery devices, such as insulin pens, pumps, and continuous glucose monitors, are enhancing patient compliance and treatment outcomes.
High insulin costs and the complexity of distribution networks remain major market restraints.
Key market players include Novo Nordisk, Eli Lilly, and Sanofi, with biosimilars and insulin delivery systems becoming focal points for competition.
Regionally, the Southern and Midwestern U.S. have the highest demand, driven by higher diabetes rates, while the Western and Northeastern regions focus on advanced technologies.

Report Scope

This report segments the United States Human Insulin Market as follows:

Market Drivers

Rising Prevalence of Diabetes

One of the primary drivers of the United States Human Insulin market is the increasing prevalence of diabetes. As of recent statistics, over 37 million people in the U.S. have diabetes, with many of them relying on insulin for effective management of the condition. Both type 1 and type 2 diabetes are becoming more common due to factors like sedentary lifestyles, poor dietary habits, and genetic predispositions. The growing number of diabetes cases necessitates an increased demand for insulin therapies, driving market growth. Additionally, the increasing incidence of prediabetes, which often progresses to type 2 diabetes, creates a larger patient pool that will eventually require insulin treatment. This trend highlights the urgent need for effective insulin management solutions, propelling market expansion.

Technological Advancements in Insulin Delivery

Technological advancements in insulin delivery systems play a significant role in driving the U.S. human insulin market. Insulin pens, pumps, and continuous glucose monitoring (CGM) devices have transformed the way insulin is administered and monitored. For instance, diabetes management tools such as automated insulin delivery systems and connected insulin pens have experienced exponential growth in the U.S. These innovations have made insulin use more efficient, convenient, and accurate, offering patients improved quality of life. Insulin pumps, for instance, provide continuous insulin delivery, eliminating the need for multiple daily injections and ensuring more stable blood glucose levels. The integration of insulin delivery devices with smartphones and wearables has made real-time monitoring and dosage adjustments possible, further enhancing patient compliance and treatment outcomes. The continuous improvement in delivery systems, combined with the development of closed-loop systems (artificial pancreas), will continue to push market growth as more patients opt for these advanced treatment options.

Aging Population

The aging U.S. population is another critical driver of the human insulin market. Older adults are at a higher risk of developing type 2 diabetes, particularly as they face changes in metabolism and activity levels with age. For instance, according to the Centers for Disease Control and Prevention (CDC), nearly 26% of adults aged 65 and older have diabetes. This demographic shift is leading to an increase in demand for insulin and diabetes management solutions. Furthermore, older individuals often require more personalized insulin regimens due to the presence of comorbidities and age-related changes in insulin sensitivity. As the proportion of elderly individuals grows, the need for insulin therapies tailored to their specific health profiles will continue to drive market growth. The rising number of elderly patients places additional pressure on healthcare systems to provide accessible and effective insulin treatments, further fostering market expansion.

Growing Healthcare Awareness and Accessibility

An increasing focus on healthcare awareness and accessibility is significantly contributing to the growth of the human insulin market in the United States. As patients become more informed about diabetes and its long-term complications, there is a heightened demand for better treatment options. Educational campaigns, government initiatives, and advocacy groups are working to raise awareness about the importance of diabetes prevention, early detection, and proper disease management. In parallel, insurance coverage for diabetes care has been expanding, improving access to insulin for patients from diverse socioeconomic backgrounds. Additionally, the push towards preventive care and early intervention is encouraging individuals at risk of diabetes to seek professional help before the disease progresses, thus increasing the potential for insulin treatment. As healthcare systems evolve to support preventive measures and improve access to necessary therapies, the demand for human insulin products is expected to remain strong.

Market Trends

Introduction of Biosimilar Insulin Products

The U.S. human insulin market is seeing a notable trend with the rise of biosimilar insulin products. These are near-identical copies of branded insulin products, which are introduced after the original product’s patent expires. Biosimilars are a game-changer in the insulin market as they offer a more affordable alternative to costly branded insulins. The introduction of biosimilar insulins aims to address the rising costs of diabetes treatment, making insulin more accessible to a broader population. For instance, the FDA’s approval of rapid-acting insulin biosimilars such as Merilog (similar to NovoLog) and Basaglar (similar to Lantus) has paved the way for greater market competition. These biosimilars offer similar efficacy and safety profiles as the original insulins, but at a reduced price, which is particularly beneficial for individuals with high out-of-pocket costs. As biosimilars continue to gain traction in the market, they are expected to drive down insulin prices and provide more affordable treatment options for diabetes patients.

Advancements in Insulin Delivery Devices

Technological advancements in insulin delivery devices are transforming the way diabetes patients manage their condition. Insulin pens, pumps, and continuous glucose monitoring (CGM) systems are revolutionizing diabetes care by offering more precise, convenient, and efficient ways to administer insulin. The evolution of insulin pens, for example, has made insulin injection easier, as they are more discreet and user-friendly compared to traditional syringes. Additionally, insulin pumps allow for continuous delivery of insulin, mimicking the body’s natural insulin release. These systems are particularly beneficial for people with type 1 diabetes, as they offer tighter glucose control and reduce the need for multiple daily injections. Continuous glucose monitoring systems further enhance this by providing real-time glucose readings, enabling users to make timely adjustments to their insulin dosage. The combination of these advanced devices is not only improving patient outcomes but also boosting adherence to treatment regimens. Moreover, the integration of artificial intelligence and machine learning with insulin delivery systems is pushing the boundaries of personalized care, making insulin therapy more tailored to individual patient needs. This trend is expected to continue driving the market as more patients and healthcare providers opt for advanced insulin management solutions.

Legislative Efforts to Cap Insulin Costs

A significant trend in the U.S. human insulin market is the growing legislative efforts to address the escalating cost of insulin. The high price of insulin has been a longstanding issue, with many patients struggling to afford their treatment. In response, several legislative initiatives have been introduced to help lower the cost of insulin for consumers. For instance, the American Diabetes Association outlines bipartisan federal legislation aimed at improving insulin affordability, including the Affordable Insulin Now Act and provisions within the Inflation Reduction Act. In addition, the Inflation Reduction Act, signed into law in 2022, includes provisions to cap the out-of-pocket cost of insulin for Medicare beneficiaries. These efforts reflect growing awareness and concern over the affordability of essential medications and have garnered support from both lawmakers and advocacy groups. While some bills are still under negotiation, these legislative measures are likely to reshape the insulin market by reducing costs and improving access for a broader range of patients.

Regulatory Scrutiny of Pharmacy Benefit Managers (PBMs)

Pharmacy Benefit Managers (PBMs) are under increasing regulatory scrutiny due to their role in the rising cost of insulin. PBMs serve as intermediaries between drug manufacturers, insurers, and pharmacies, negotiating rebates and discounts on medications. However, critics argue that the rebate system used by PBMs often leads to inflated drug prices, including the cost of insulin. In particular, some reports suggest that PBMs prioritize high-cost insulins that offer greater rebates, which leads to higher prices for consumers. In response to these concerns, the Federal Trade Commission (FTC) has initiated investigations and legal actions against major PBMs, seeking to reform these practices and promote greater transparency in pricing. The goal is to ensure that insulin prices are more competitive and that patients do not face excessive costs due to the actions of middlemen in the supply chain. Additionally, advocacy groups have called for more stringent regulations to eliminate the conflicts of interest inherent in the PBM system.

Market Challenges Analysis

High Insulin Costs and Affordability Issues

One of the most significant challenges facing the U.S. human insulin market is the high cost of insulin, which remains a major barrier to access for many patients. Despite the availability of various insulin products, including branded and generic options, the price of insulin has been steadily increasing over the years. Patients often struggle to afford the medication, with many facing high out-of-pocket expenses, even with insurance coverage. The price discrepancies across different insulin products, compounded by insurance formulary structures and pharmacy benefit manager (PBM) practices, exacerbate the problem. For those without insurance or with inadequate coverage, the cost of insulin can be prohibitively high, leading to rationing or skipping doses. This affordability issue has sparked widespread public outcry and led to legislative efforts aimed at capping insulin prices. However, until these efforts are fully realized, the affordability of insulin will continue to be a challenge, limiting access for vulnerable populations and driving up healthcare costs overall.

Supply Chain and Distribution Challenges

The U.S. human insulin market also faces significant challenges related to supply chain and distribution issues. Insulin is a biologic drug, meaning it is complex to manufacture and requires strict storage and handling conditions to maintain its efficacy. For instance, the U.S. Census Bureau collects and produces data on various aspects of the supply chain, including foreign trade, manufacturing, and the movement of goods, which impact insulin distribution. The production of insulin is concentrated among a few major manufacturers, which can lead to supply bottlenecks, especially during periods of high demand or manufacturing disruptions. Any delays or interruptions in the production process can result in insulin shortages, leaving patients without access to necessary treatment. Additionally, the distribution network can sometimes be inefficient, with rural and underserved areas experiencing difficulties in accessing insulin. While advances in telehealth and digital pharmacy services have somewhat mitigated these issues, the physical infrastructure for insulin distribution remains a challenge. These supply chain and distribution problems are particularly concerning as the demand for insulin continues to rise due to the growing prevalence of diabetes in the U.S. Addressing these challenges will be essential to ensure a stable and equitable supply of insulin across the country.

Market Opportunities

The U.S. human insulin market presents significant opportunities driven by the increasing prevalence of diabetes and the rising demand for affordable treatment options. With the number of diabetes cases steadily growing, particularly among the aging population, the market for insulin is expected to expand further. The shift toward more accessible and cost-effective insulin therapies, such as biosimilars, provides an opportunity for manufacturers to capture a larger share of the market by offering affordable alternatives to traditional branded insulins. Biosimilars, which offer similar efficacy and safety at a lower price point, are poised to disrupt the insulin market by increasing competition and reducing the financial burden on patients. This growing demand for affordable insulin, especially in light of ongoing legislative efforts to cap insulin prices, creates a lucrative opportunity for both established and emerging companies to innovate and meet the needs of a larger, price-sensitive patient population.

Another key opportunity lies in the continued advancement of insulin delivery technologies. The development of more advanced insulin delivery systems, including insulin pumps, pens, and continuous glucose monitoring devices, presents significant growth prospects. These devices offer patients greater precision and ease of use, leading to improved treatment outcomes and better adherence to prescribed regimens. Furthermore, the integration of artificial intelligence and machine learning into insulin delivery systems enables more personalized care, offering tailored treatment plans based on real-time data. With the rising trend of remote monitoring and telemedicine, there is an increasing demand for connected devices that allow patients to manage their diabetes more effectively. This trend provides manufacturers with the chance to innovate and develop next-generation insulin delivery technologies that improve patient outcomes while expanding market reach. Additionally, the growing focus on preventive healthcare and early diabetes management presents an opportunity for the insulin market to expand into new patient segments, further driving growth.

Market Segmentation Analysis:

By Device:

The U.S. human insulin market can be segmented based on the devices used for insulin administration, which includes pens, syringes, and others. Among these, insulin pens are gaining substantial market share due to their convenience, precision, and ease of use. Insulin pens offer a discreet and portable solution for insulin administration, which has made them particularly popular among patients with type 1 and type 2 diabetes. They are user-friendly, reducing the risk of dosing errors and improving patient adherence to insulin therapy. Syringes, while still widely used, are increasingly being replaced by pens due to their more cumbersome nature and the discomfort associated with injections. However, syringes remain a cost-effective option for some patients, especially those who are uninsured or underinsured. The “Others” segment includes insulin pumps and inhalable insulin devices, which are growing in popularity, particularly among type 1 diabetes patients. These devices provide continuous insulin delivery, offering better control over blood sugar levels and enhancing the convenience of diabetes management.

By Indication:

The human insulin market in the U.S. can also be analyzed based on the indications for which insulin is prescribed: type 1 diabetes, type 2 diabetes, and gestational diabetes. Type 1 diabetes holds the largest share of the market, as patients with this condition require lifelong insulin therapy. The continuous need for insulin among type 1 diabetics drives significant demand for both rapid-acting and long-acting insulin. Type 2 diabetes, which is the most prevalent form of diabetes, also represents a substantial segment, as many patients require insulin to manage their condition after oral medications are no longer effective. As the prevalence of type 2 diabetes continues to rise, particularly due to lifestyle factors such as obesity and sedentary habits, the demand for insulin in this segment is expected to grow. Gestational diabetes, which occurs during pregnancy, represents a smaller segment but is important in the context of temporary insulin use. Although it is less common, gestational diabetes requires insulin therapy in some cases, particularly for women who cannot manage their blood sugar levels through diet and exercise alone.

Segments:

Based on Device:

Pens
Syringes
Others

Based on Indication:

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

Based on Insulin:

Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others

Based on Distribution Channel:

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

Based on the Geography:

Western United States
Midwestern United States
Southern United States
Northeastern United States

Regional Analysis

Western United States

The Western United States holds a significant portion of the market, accounting for approximately 25% of the total U.S. insulin market share. The region’s high population density and the increasing prevalence of type 2 diabetes, fueled by lifestyle factors such as high rates of obesity, have contributed to the growing demand for insulin. In addition, the presence of major healthcare and pharmaceutical companies in states like California has fostered innovation in diabetes care, particularly in insulin delivery systems and biosimilars. The Western region is also seeing rising demand for advanced technologies like insulin pumps and continuous glucose monitoring systems, making it a key growth driver in the insulin market.

Midwestern United States

The Midwestern United States represents around 22% of the U.S. human insulin market share. This region is home to a large portion of the U.S. diabetic population, particularly those affected by type 2 diabetes. Factors such as higher rates of obesity and aging demographics in the Midwest have contributed to a growing number of diabetes cases, which in turn drives insulin demand. Additionally, the region’s relatively lower cost of living and healthcare allow more patients to access insulin treatments, supporting continued market growth. The Midwestern U.S. is also benefiting from expanding healthcare infrastructure, improving patient access to insulin and diabetes care services.

Southern United States

In the Southern United States, the human insulin market holds a market share of approximately 30%. The South is home to a higher concentration of diabetes cases, particularly in states like Texas, Alabama, and Louisiana, where obesity rates are among the highest in the country. This has led to a strong demand for insulin therapies, particularly for type 2 diabetes. The region’s healthcare providers are increasingly focused on improving diabetes management through better access to insulin and the adoption of newer, more efficient insulin delivery technologies. However, the Southern U.S. also faces challenges, such as socioeconomic disparities and limited access to healthcare in rural areas, which can impact insulin affordability and distribution.

Northeastern United States

The Northeastern United States holds a market share of around 23%, with a growing demand for human insulin driven by a combination of an aging population and higher rates of chronic conditions like diabetes. The Northeast, including states such as New York, Pennsylvania, and New Jersey, sees a substantial proportion of patients with type 1 diabetes, particularly in urban centers with large populations. The region also benefits from a robust healthcare system and a high level of awareness about diabetes management, which supports insulin use. However, despite strong infrastructure, the region’s high living costs and variations in insurance coverage can affect patient access to affordable insulin, making affordability a critical issue in some areas. As such, market growth in the Northeast continues to be influenced by both healthcare policies and regional demographics.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Novo Nordisk A/S
MannKind Corporation
Pfizer
Wockhardt
Biocon
Lupin
Tonghua Dongbao Pharmaceutical Co
Eli Lilly and Company

Competitive Analysis

The U.S. human insulin market is highly competitive, dominated by a few leading global players. These include Novo Nordisk, Eli Lilly, Sanofi, MannKind Corporation, Pfizer, Wockhardt, Biocon, Lupin, Tonghua Dongbao Pharmaceutical Co. and others. Among these, Novo Nordisk and Eli Lilly hold the largest market shares, driven by their extensive portfolios of insulin products, including both rapid-acting and long-acting insulins. These companies have established a strong presence in both branded and biosimilar insulin products, offering patients a wide range of treatment options. The market is increasingly driven by innovations in insulin delivery systems, such as insulin pens, pumps, and continuous glucose monitoring devices, which are improving treatment outcomes and patient compliance. Additionally, the growing popularity of biosimilar insulins is intensifying competition, as these alternatives offer lower-priced options while maintaining similar efficacy and safety to branded insulins. Biosimilars, in particular, are emerging as key products in the market, addressing the affordability concerns faced by many diabetic patients. As these products gain approval and become more widely available, they are likely to capture a significant share of the market, especially in the face of ongoing price pressures. Furthermore, advancements in insulin delivery technology, such as the integration of artificial intelligence and data-driven systems, are likely to disrupt the market by offering more personalized treatment regimens. These developments are expected to lead to heightened competition among companies striving to meet the evolving needs of patients and healthcare providers. As a result, market players will need to continually innovate to maintain their competitive edge and capture the growing demand for insulin therapies.

Recent Developments

In April 2025, Novo Nordisk announced the discontinuation of Human Mixtard, India’s largest-selling human insulin brand, as part of a global strategy to prioritize newer, patented diabetes and weight loss therapies such as Ozempic and Wegovy. While vial forms of Mixtard, Actrapid, and Insulatard will remain available, pen devices (Penfills and FlexPens) are being phased out, which is expected to disrupt patient access and preference in India.
In April 2025, Pfizer discontinued the development of danuglipron, its once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes, following a case of drug-induced liver injury and after reviewing clinical and regulatory feedback. This decision halts further clinical development for both obesity and diabetes indications.
In March 2025, Biocon Biologics entered a strategic collaboration with Civica, Inc. to expand access to Insulin Aspart in the United States. Biocon will supply the drug substance, which Civica will formulate and commercialize after completing development and clinical trials.
In December 2024, Lupin acquired the Huminsulin® portfolio in India from Eli Lilly and Company. The range includes Insulin Human (Huminsulin R, NPH, 50/50, and 30/70) and is indicated for type 1 and type 2 diabetes. Lupin had previously marketed these products under a distribution agreement, and the acquisition is aimed at strengthening its diabetes portfolio.
In November 2024, MannKind’s Afrezza® (insulin human) Inhalation Powder received approval from India’s CDSCO. MannKind expects to ship product to its partner Cipla by the end of 2025.
In October 2024, Wockhardt filed for approval of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). The product, developed indigenously, will be offered in cartridges, vials, and prefilled disposable pens. This expands Wockhardt’s diabetes biosimilars portfolio and addresses a market with limited competition.

Market Concentration & Characteristics

The U.S. human insulin market is characterized by moderate to high concentration, with a few dominant players controlling the majority of market share. These major companies offer a wide range of insulin products, including both traditional and biosimilar insulins, catering to the growing demand for diabetes management solutions. Market characteristics include significant competition driven by both branded insulin therapies and cost-effective biosimilar alternatives. While large pharmaceutical companies hold a dominant position, there is also a growing presence of emerging players focusing on biosimilars, which have gained traction due to their affordability compared to branded insulins. The market is also marked by continuous innovation in insulin delivery systems, such as insulin pumps and continuous glucose monitoring devices, which enhance patient outcomes and compliance. Additionally, legislative efforts to reduce insulin costs are influencing market dynamics, encouraging companies to focus on pricing strategies and improve access to insulin therapies. This competitive landscape is set to evolve with new technological advancements and regulatory changes.

Report Coverage

The research report offers an in-depth analysis based on Device, Indication, Insulin, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The U.S. human insulin market is expected to continue growing due to the increasing prevalence of diabetes.
Biosimilar insulins are likely to capture a larger market share, driven by their affordability compared to branded options.
Advancements in insulin delivery technologies, such as insulin pumps and continuous glucose monitoring systems, will enhance patient outcomes.
Legislative efforts to cap insulin prices are anticipated to improve access and affordability for patients.
The growing demand for personalized diabetes care will drive the development of tailored insulin regimens and treatment plans.
Increasing adoption of digital health tools and telemedicine will play a key role in diabetes management, influencing insulin usage.
The market will see continued competition among major pharmaceutical companies and emerging biosimilar producers.
The integration of artificial intelligence in insulin delivery devices will improve precision and real-time glucose management.
Rising healthcare awareness and early diabetes detection will lead to increased insulin demand across various patient demographics.
Greater focus on preventive healthcare and lifestyle management will potentially slow the progression of diabetes, affecting insulin consumption trends.

CHAPTER NO. 1 : INTRODUCTION 19

1.1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.1.2. Key Benefits for Stakeholders 19

1.1.3. Target Audience 20

1.1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. Human Insulin Market Snapshot 21

2.1.1. United States Human Insulin Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23

3.1. Russia-Ukraine and Israel-Palestine War Impacts 23

CHAPTER NO. 4 : HUMAN INSULIN MARKET – INDUSTRY ANALYSIS 24

4.1. Introduction 24

4.2. Market Drivers 25

4.2.1. Driving Factor 1 Analysis 25

4.2.2. Driving Factor 2 Analysis 26

4.3. Market Restraints 27

4.3.1. Restraining Factor Analysis 27

4.4. Market Opportunities 28

4.4.1. Market Opportunity Analysis 28

4.5. Porter’s Five Forces Analysis 29

4.6. Value Chain Analysis 30

4.7. Buying Criteria 31

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32

5.1. Import Analysis by United States 32

5.1.1. United States Human Insulin Market Import Volume/Revenue, By United States, 2018 – 2023 32

5.2. Export Analysis by United States 33

5.2.1. United States Human Insulin Market Export Volume/Revenue, By United States, 2018 – 2023 33

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34

6.1. Demand Analysis by United States 34

6.1.1. United States Human Insulin Market Demand Volume/Revenue, By United States, 2018 – 2023 34

6.2. Supply Analysis by United States 35

6.2.1. United States Human Insulin Market Supply Volume/Revenue, By United States, 2018 – 2023 35

CHAPTER NO. 7 : PRODUCTION ANALYSIS 36

7.1. Production Analysis by United States 36

7.1.1. United States Human Insulin Market Production Volume/Revenue, By United States, 2018 – 2023 36

CHAPTER NO. 8 : PRICE ANALYSIS 37

8.1. Price Analysis by Type 37

8.1.1. United States Human Insulin Market Price, By Type, 2018 – 2023 37

8.1.2. United States Type Market Price, By Type, 2018 – 2023 37

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38

9.1. Key Raw Materials and Suppliers 38

9.2. Key Raw Materials Price Trend 38

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39

10.1. Manufacturing Cost Analysis 39

10.2. Manufacturing Process 39

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40

11.1. Company Market Share Analysis – 2023 40

11.1.1. United States Human Insulin Market: Company Market Share, by Volume, 2023 40

11.1.2. United States Human Insulin Market: Company Market Share, by Revenue, 2023 41

11.1.3. United States Human Insulin Market: Top 6 Company Market Share, by Revenue, 2023 41

11.1.4. United States Human Insulin Market: Top 3 Company Market Share, by Revenue, 2023 42

11.2. United States Human Insulin Market Company Volume Market Share, 2023 43

11.3. United States Human Insulin Market Company Revenue Market Share, 2023 44

11.4. Company Assessment Metrics, 2023 45

11.4.1. Stars 45

11.4.2. Emerging Leaders 45

11.4.3. Pervasive Players 45

11.4.4. Participants 45

11.5. Start-ups /SMEs Assessment Metrics, 2023 45

11.5.1. Progressive Companies 45

11.5.2. Responsive Companies 45

11.5.3. Dynamic Companies 45

11.5.4. Starting Blocks 45

11.6. Strategic Developments 46

11.6.1. Acquisitions & Mergers 46

New Product Launch 46

United States Expansion 46

11.7. Key Players Product Matrix 47

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48

12.1. PESTEL 48

12.1.1. Political Factors 48

12.1.2. Economic Factors 48

12.1.3. Social Factors 48

12.1.4. Technological Factors 48

12.1.5. Environmental Factors 48

12.1.6. Legal Factors 48

12.2. Adjacent Market Analysis 48

CHAPTER NO. 13 : HUMAN INSULIN MARKET – BY TYPE SEGMENT ANALYSIS 49

13.1. Human Insulin Market Overview, by Type Segment 49

13.1.1. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50

13.1.2. Human Insulin Market Attractiveness Analysis, By Type 51

13.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 51

13.1.4. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

13.2. Pens 53

13.3. Syringes 54

13.4. Others 55

13.5. Type 4 56

13.6. Type 5 57

CHAPTER NO. 14 : HUMAN INSULIN MARKET – BY APPLICATION SEGMENT ANALYSIS 58

14.1. Human Insulin Market Overview, by Application Segment 58

14.1.1. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59

14.1.2. Human Insulin Market Attractiveness Analysis, By Application 60

14.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 60

14.1.4. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

14.2. Type 1 Diabetes 62

14.3. Type 2 Diabetes 63

14.4. Gestational Diabetes 64

14.5. Application 4 65

14.6. Application 5 66

CHAPTER NO. 15 : HUMAN INSULIN MARKET – BY END-USER SEGMENT ANALYSIS 67

15.1. Human Insulin Market Overview, by End-user Segment 67

15.1.1. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68

15.1.2. Human Insulin Market Attractiveness Analysis, By End-user 69

15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 69

15.1.4. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

15.2. Rapid-acting insulin 71

15.3. Short-acting insulin 72

15.4. Intermediate-acting insulin 73

15.5. Others 74

15.6. End-user 5 75

CHAPTER NO. 16 : HUMAN INSULIN MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 76

16.1. Human Insulin Market Overview, by Technology Segment 76

16.1.1. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77

16.1.2. Human Insulin Market Attractiveness Analysis, By Technology 78

16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 78

16.1.4. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

16.2. Technology 1 80

16.3. Technology 2 81

16.4. Technology 3 82

CHAPTER NO. 17 : – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 83

17.1. Human Insulin Market Overview, by Distribution Channel Segment 83

17.1.1. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84

17.1.2. Human Insulin Market Attractiveness Analysis, By Distribution Channel 85

17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 85

17.1.4. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

17.2. Hospital Pharmacies 87

17.3. Drug Stores and Retail Pharmacies 88

17.4. Online Providers 89

17.5. Distribution Channel 4 90

17.6. Distribution Channel 5 91

CHAPTER NO. 18 : HUMAN INSULIN MARKET – UNITED STATES ANALYSIS 92

18.1. Type 92

18.1.1. United States Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 92

18.2. United States Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 92

18.3. Application 93

18.3.1. United States Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 93

18.3.2. United States Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 93

18.4. End-user 94

18.4.1. United States Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 94

18.4.2. United States Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 94

18.5. Technology 95

18.5.1. United States Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 95

18.5.2. United States Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 95

18.6. Distribution Channel 96

18.6.1. United States Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 96

18.6.2. United States Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 96

CHAPTER NO. 19 : COMPANY PROFILES 97

19.1. Novo Nordisk A/S 97

19.1.1. Company Overview 97

19.1.2. Product Portfolio 97

19.1.3. Swot Analysis 97

19.1.4. Business Strategy 98

19.1.5. Financial Overview 98

19.1.6. MannKind Corporation 99

19.1.7. Pfizer 99

19.1.8. Wockhardt 99

19.1.9. Biocon 99

19.1.10. Lupin 99

19.1.11. Tonghua Dongbao Pharmaceutical Co 99

19.1.12. Eli Lilly and Company 99

19.1.13. Company 9 99

19.1.14. Company 10 99

19.1.15. Company 11 99

19.1.16. Company 12 99

19.1.17. Company 13 99

19.1.18. Company 14 99

CHAPTER NO. 20 : RESEARCH METHODOLOGY 100

20.1. Research Methodology 100

20.1.1. Phase I – Secondary Research 101

20.1.2. Phase II – Data Modeling 101

Company Share Analysis Model 102

Revenue Based Modeling 102

20.1.3. Phase III – Primary Research 103

20.1.4. Research Limitations 104

Assumptions 104

List of Figures

FIG NO. 1. United States Human Insulin Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for United States Human Insulin Market 29

FIG NO. 3. Value Chain Analysis for United States Human Insulin Market 30

FIG NO. 4. United States Human Insulin Market Import Volume/Revenue, By United States, 2018 – 2023 32

FIG NO. 5. United States Human Insulin Market Export Volume/Revenue, By United States, 2018 – 2023 33

FIG NO. 6. United States Human Insulin Market Demand Volume/Revenue, By United States, 2018 – 2023 34

FIG NO. 7. United States Human Insulin Market Supply Volume/Revenue, By United States, 2018 – 2023 35

FIG NO. 8. United States Human Insulin Market Production Volume/Revenue, By United States, 2018 – 2023 36

FIG NO. 9. United States Human Insulin Market Price, By Type, 2018 – 2023 37

FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38

FIG NO. 11. Manufacturing Cost Analysis 39

FIG NO. 12. Manufacturing Process 39

FIG NO. 13. Company Share Analysis, 2023 40

FIG NO. 14. Company Share Analysis, 2023 41

FIG NO. 15. Company Share Analysis, 2023 41

FIG NO. 16. Company Share Analysis, 2023 42

FIG NO. 17. Human Insulin Market – Company Volume Market Share, 2023 43

FIG NO. 18. Human Insulin Market – Company Revenue Market Share, 2023 44

FIG NO. 19. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50

FIG NO. 20. Market Attractiveness Analysis, By Type 51

FIG NO. 21. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 51

FIG NO. 22. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

FIG NO. 23. United States Human Insulin Market for Pens, Revenue (USD Million) 2018 – 2032 53

FIG NO. 24. United States Human Insulin Market for Syringes, Revenue (USD Million) 2018 – 2032 54

FIG NO. 25. United States Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 55

FIG NO. 26. United States Human Insulin Market for Type 4, Revenue (USD Million) 2018 – 2032 56

FIG NO. 27. United States Human Insulin Market for Type 5, Revenue (USD Million) 2018 – 2032 57

FIG NO. 28. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59

FIG NO. 29. Market Attractiveness Analysis, By Application 60

FIG NO. 30. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 60

FIG NO. 31. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

FIG NO. 32. United States Human Insulin Market for Type 1 Diabetes, Revenue (USD Million) 2018 – 2032 62

FIG NO. 33. United States Human Insulin Market for Type 2 Diabetes, Revenue (USD Million) 2018 – 2032 63

FIG NO. 34. United States Human Insulin Market for Gestational Diabetes, Revenue (USD Million) 2018 – 2032 64

FIG NO. 35. United States Human Insulin Market for Application 4, Revenue (USD Million) 2018 – 2032 65

FIG NO. 36. United States Human Insulin Market for Application 5, Revenue (USD Million) 2018 – 2032 66

FIG NO. 37. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68

FIG NO. 38. Market Attractiveness Analysis, By End-user 69

FIG NO. 39. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 69

FIG NO. 40. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

FIG NO. 41. United States Human Insulin Market for Rapid-acting insulin, Revenue (USD Million) 2018 – 2032 71

FIG NO. 42. United States Human Insulin Market for Short-acting insulin, Revenue (USD Million) 2018 – 2032 72

FIG NO. 43. United States Human Insulin Market for Intermediate-acting insulin, Revenue (USD Million) 2018 – 2032 73

FIG NO. 44. United States Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 74

FIG NO. 45. United States Human Insulin Market for End-user 5, Revenue (USD Million) 2018 – 2032 75

FIG NO. 46. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77

FIG NO. 47. Market Attractiveness Analysis, By Technology 78

FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78

FIG NO. 49. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

FIG NO. 50. United States Human Insulin Market for Technology 1, Revenue (USD Million) 2018 – 2032 80

FIG NO. 51. United States Human Insulin Market for Technology 2, Revenue (USD Million) 2018 – 2032 81

FIG NO. 52. United States Human Insulin Market for Technology 3, Revenue (USD Million) 2018 – 2032 82

FIG NO. 53. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84

FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85

FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85

FIG NO. 56. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

FIG NO. 57. United States Human Insulin Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 87

FIG NO. 58. United States Human Insulin Market for Drug Stores and Retail Pharmacies, Revenue (USD Million) 2018 – 2032 88

FIG NO. 59. United States Human Insulin Market for Online Providers, Revenue (USD Million) 2018 – 2032 89

FIG NO. 60. United States Human Insulin Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90

FIG NO. 61. United States Human Insulin Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91

FIG NO. 62. Research Methodology – Detailed View 100

FIG NO. 63. Research Methodology 101

List of Tables

TABLE NO. 1. : United States Human Insulin Market: Snapshot 18

TABLE NO. 2. : Drivers for the Human Insulin Market: Impact Analysis 22

TABLE NO. 3. : Restraints for the Human Insulin Market: Impact Analysis 24

TABLE NO. 4. : United States Human Insulin Market Revenue, By Type, 2018 – 2023 34

TABLE NO. 5. : Key Raw Materials & Suppliers 35

TABLE NO. 6. : United States Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 89

TABLE NO. 7. : United States Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 89

TABLE NO. 8. : United States Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 90

TABLE NO. 9. : United States Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 90

TABLE NO. 10. : United States Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 91

TABLE NO. 11. : United States Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 91

TABLE NO. 12. : United States Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 92

TABLE NO. 13. : United States Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 92

TABLE NO. 14. : United States Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93

TABLE NO. 15. : United States Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93

Frequently Asked Questions

What is the current size of the United States Human Insulin?

The United States Human Insulin market was valued at USD 6,123.09 million in 2023 and is projected to reach USD 9,178.30 million by 2032, growing at a CAGR of 4.60%.

What factors are driving the growth of the United States Human Insulin?

Growth is driven by the rising prevalence of diabetes, technological advancements in insulin delivery systems, an aging population, and increasing healthcare awareness.

What are some challenges faced by the United States Human Insulin?

Challenges include high insulin costs, affordability issues, complex supply chains, and distribution challenges, especially in rural areas.

Who are the major players in the United States Human Insulin?

Major players include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, MannKind Corporation, Pfizer, Biocon, Wockhardt, and Lupin

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$8699

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –